切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2016, Vol. 05 ›› Issue (03) : 114 -117. doi: 10.3877/cma.j.issn.2095-3216.2016.03.005

所属专题: 文献

专家论坛

腹膜透析非感染相关并发症的防治
方炜1,(), 刘曜蓉1   
  1. 1. 200127 上海交通大学医学院附属仁济医院肾脏科,上海市腹膜透析研究中心
  • 收稿日期:2016-04-21 出版日期:2016-06-28
  • 通信作者: 方炜
  • 基金资助:
    上海交通大学医学院高原高峰之双百人计划"研究型医师"项目(20152211); 上海市科委项目(114119a5900)

Prevention and treatment of noninfectious complications in patients under peritoneal dialysis

Wei Fang1,(), Yaorong Liu1   

  1. 1. Department of Nephrology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Research Centre for Peritoneal Dialysis, Shanghai 200127, China
  • Received:2016-04-21 Published:2016-06-28
  • Corresponding author: Wei Fang
  • About author:
    Corresponding author: Fang Wei, Email:
引用本文:

方炜, 刘曜蓉. 腹膜透析非感染相关并发症的防治[J]. 中华肾病研究电子杂志, 2016, 05(03): 114-117.

Wei Fang, Yaorong Liu. Prevention and treatment of noninfectious complications in patients under peritoneal dialysis[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2016, 05(03): 114-117.

随着腹膜透析的广泛应用及长龄腹膜透析患者的增加,腹膜透析非感染相关并发症的发生日渐增多。腹膜透析非感染相关并发症主要包括导管相关并发症、腹膜透析液留腹引起的腹内压增加相关并发症和代谢并发症等。积极预防和治疗非感染相关并发症是改善腹膜透析患者预后的重要措施之一。

Peritoneal dialysis (PD) has been widely applied for treating patients with end-stage renal disease, and the number of long-term PD patients has continuously increased. Noninfectious complications are emerging as an important cause for technique failure of PD, including catheter-related complications, increased intra-abdominal pressure-related complications, and metabolic complications. Active prevention and treatment of these noninfectious complications are important for improving the outcomes of PD patients.

[1]
Lo WK. Peritoneal dialysis in the Far East-an astonishing situation in 2008[J]. Perit Dail Int, 2009, 29 (Suppl 2): 227-229.
[2]
Cho Y,Johnson DW. Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes[J]. Am J Kidney Dis, 2014, 64(2): 278-289.
[3]
Leung CB,Cheung WL,Li PK. Renal registry in Hong Kong-the first 20 years[J]. Kidney Int Suppl, 2015, 5(1): 33-38.
[4]
Schaubel DE,Blake PG,Fenton SSA. Trends in CAPD technique failure: Canada 1981-1997[J]. Perit Dial Int, 2001, 21(4): 365-371.
[5]
Mujais S,Story K. Peritoneal dialysis in the US: Evaluation of outcomes in contemporary cohorts[J]. Kidney Int Suppl, 2006, 103: S21-S26.
[6]
Fang W,Qian J,Lin A, et al. Comparison of peritoneal dialysis practice patterns and outcomes between a Canadian and a Chinese centre[J]. Nephrol Dial Transplant, 2008, 23(12): 4021-4028.
[7]
Liu Y,Zhang L,Lin A, et al. Impact of break-in period on the short-term outcomes of patients started on peritoneal dialysis[J]. Peri Dial Int, 2014, 34(1): 49-56.
[8]
Figueiredo A,Goh BL,Jenkins S, et al. Clinical practice guidelines for peritoneal access[J]. Perit Dial Int, 2010, 30(4): 424-429.
[9]
Gadallah MF,Mignone J,Torres C, et al. The role of peritoneal dialysis catheter configuration in preventing catheter tip migration[J]. Adv Perit Dial, 2000, 16: 47-50.
[10]
Flanigan M,Gokal R. Peritoneal catheters and exit-site practices toward optimum peritoneal access: a review of current developments[J]. Perit Dial Int, 2005, 25(2): 132-139.
[11]
Crabtree JH,Burchette RJ,Siddiqi NA. Optimal peritoneal dialysis catheter type and exit site location: an anthropometric analysis[J]. ASAIO J, 2005, 51(6): 743-747.
[12]
Oqünç G,Tuncer M,Oqünç D, et al. Laparoscopic omenal fixation technique versus open surgical placement of peritoneal dialysis catheters[J]. Surg Endosc, 2003, 17(11): 1749-1755.
[13]
Crabtree JH. Development of surgical guidelines for laparoscopic peritoneal dialysis access: down a long and winding road[J]. Perit Dial Int, 2015, 35(3): 241-244.
[14]
Tu WT,Su Z,Shan YS. An original non-traumatic maneuver for repositioning migrated peritoneal dialysis catheters[J]. Perit Dial Int, 2009, 29(3): 325-329.
[15]
Zorzanello MM,Fleming WJ,Prowant BE. Use of tissue plasminogen activator in peritoneal dialysis catheters: A literature review and one center′s experience[J]. Nephrol Nurs J, 2004, 31(5): 534-537.
[16]
王琴,倪兆慧,朱铭力, 等. 腹腔CT影像学检查在腹膜透析相关非感染性腹腔并发症中的诊断价值[J]. 中西医结合学报, 2008, 6(5): 478-481.
[17]
Bargman JM. Complications of peritoneal dialysis related to increased intraabdominal pressure[J]. Kidney Int Suppl, 1993, 40: S75-S80.
[18]
Garcia-Urena MA,Rodriguez CR,Vega Ruiz, et al. Prevalence and management of hernias in peritoneal dialysis patients[J]. Perit Dial Int, 2006, 26(2): 198-202.
[19]
Crabtree JH. Hernia repair without delay in initiation or continuing peritoneal dialysis[J]. Perit Dial Int, 2006, 26(2): 178-182.
[20]
Shah H,Chu M,Bargman JM. Perioperative management of peritoneal dialysis patients undergoing hernia surgery without the use of interim hemodialysis[J]. Perit Dial Int, 2006, 26(6): 684-687.
[21]
Bargman JM. Hernias in peritoneal dialysis patients: limiting occurrence and recurrence[J]. Perit Dial Int, 2008, 28(4): 349-351.
[22]
卞正乾,钟鸣,林爱武, 等. 腹膜透析病人合并腹壁疝的临床诊治体会[J]. 外科理论与实践, 2009, 14(4): 415-419.
[23]
Yoon CY,Lee Mj,Kee YK, et al. Insulin resistance is associated with new-onset cardiovascular events in nondiabetic patients undergoing peritoneal dialysis[J]. Kidney Res Clin Pract, 2014, 33(4): 192-198.
[24]
Cao L,Mou S,Fang W, et al. Hyperleptinaemia, insulin resistance and survival in peritoneal dialysis patients[J]. Nephrology (Carlton), 2015, 20(9): 617-624.
[25]
Selby NM,Fialova J,Burton JO, et al. The haemodynamic and metabolic effects of hypertonic-glucose and amino-acid based peritoneal dialysis fluids[J]. Nephrol Dial Transplant, 2007, 22(3): 870-879.
[26]
Bernardo AP,Oliveira JC,Santos O, et al. Insulin resistance in nondiabetic peritoneal dialysis patients: associations with body composition, peritoneal transport, and peritoneal glucose absorption[J]. Clin J Am Soc Nephrol, 2015, 10(12): 2205-2012.
[27]
Szeto CC,Chow KM,Kwan BC, et al. New-onset hyperglycemia in nondiabetic Chinese patients started on peritoneal dialysis[J]. Am J Kidney Dis, 2007, 49(4): 524-532.
[28]
Oba T,Mori T,Chida M, et al. Glucose and insulin response to Peritoneal dialysis fluid in diabetic and nondiabetic peritoneal dialysis patients[J]. Adv Perit Dial, 2015, 31: 11-16.
[29]
Wallace AM,McMahon AD,Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS)[J]. Circulation, 2001, 104(25): 3052-3056.
[30]
Kim DJ,Oh DJ,Kim B, et al. The effect of continuous ambulatory peritoneal dialysis on change in serum leptin[J]. Perit Dial Int, 1999, 19(Suppl 2): S172-S175.
[31]
Teta D,Tedjani A,Burnier M, et al. Glucose-containing peritoneal dialysis fluids regulate leptin secretion from 3T3-L1 adipocytes[J]. Nephrol Dial Transplant, 2005, 20(7): 1329-1335.
[32]
Moberly JB,Mujais S,Gehr T, et al. Pharmacokinetics of icodextrin in peritoneal dialysis patients[J]. Kidney Int Suppl, 2002, 81: S23-S33.
[33]
Furuya R,Odamaki M,Kumagai H, et al. Beneficial effects of icodextrin on plasma levels of adipocytokines in peritoneal dialysis patients[J]. Nephrol Dial Transplant, 2006, 21(2): 494-498.
[34]
Little J,Phillips I,Russel I, et al. Longitudinal lipid profiles on CAPD: their relationship to weight gain, comorbidity, and dialysis factor[J]. J Am Soc Nephrol, 1998, 9(10): 1931-1939.
[35]
Li PK,Culleton BF,Ariza A, et al. Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients[J]. J Am Soc Nephrol, 2013, 24(11): 1889-1900.
[1] 衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[2] 谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[3] 杨小菁, 姜瑞瑞, 石玉香, 王静静, 李长天. 乳腺孤立性纤维性肿瘤一例[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 375-377.
[4] 张伟. 牙及牙槽外科:舒适治疗的先锋[J]. 中华口腔医学研究杂志(电子版), 2023, 17(06): 386-388.
[5] 彭旭, 邵永孚, 李铎, 邹瑞, 邢贞明. 结肠肝曲癌的诊断和外科治疗[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 108-110.
[6] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[7] 杨瑞洲, 李国栋, 吴向阳. 腹股沟疝术后感染的治疗方法探讨[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 715-719.
[8] 徐金林, 陈征. 抗菌药物临床应用监测对腹股沟疝修补术预防用药及感染的影响[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 720-723.
[9] 蓝冰, 王怀明, 王辉, 马波. 局部晚期结肠癌膀胱浸润的研究进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 505-511.
[10] 陆志峰, 周佳佳, 梁舒. 虚拟现实技术在治疗弱视中的临床应用研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 891-895.
[11] 李田, 徐洪, 刘和亮. 尘肺病的相关研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 900-905.
[12] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
[13] 李变, 王莉娜, 桑田, 李珊, 杜雪燕, 李春华, 张兴云, 管巧, 王颖, 冯琪, 蒙景雯. 亚低温技术治疗缺氧缺血性脑病新生儿的临床分析[J]. 中华临床医师杂志(电子版), 2023, 17(06): 639-643.
[14] 戴俊, 李硕, 曹影, 汪守峰, 宋红毛, 蔡菁菁, 邵敏, 陈莉, 程雷, 怀德. 鼻内镜下改良高选择性翼管神经低温等离子消融术对中重度变应性鼻炎的效果研究[J]. 中华临床医师杂志(电子版), 2023, 17(06): 689-693.
[15] 符梅沙, 周玉华, 李慧, 薛春颜. 淋巴细胞免疫治疗对复发性流产患者外周血T淋巴细胞亚群分布与PD1/PD-L1表达的影响及意义[J]. 中华临床医师杂志(电子版), 2023, 17(06): 726-730.
阅读次数
全文


摘要